BioPorto1,588 DKK +2,45 %
HC Andersen Capital saa maksun yhtiöltä BioPorto DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.Lue lisää